AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit Agreement March 30, 2021Deposit Agreement • March 1st, 2022 • Achilles Therapeutics PLC • Biological products, (no disgnostic substances) • New York
DEPOSIT AGREEMENT dated as of March 30, 2021 among ACHILLES THERAPEUTICS PLC, a company incorporated under the laws of England and Wales (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
LICENCE AGREEMENTLicence Agreement • March 10th, 2021 • Achilles Therapeutics PLC • Biological products, (no disgnostic substances) • England
the course of and ongoing performance of the TRACERx Study in other fields as specified in this Agreement, as well as a right to negotiate for a licence over Founders IP which will arise after the Effective Date for a defined period, in each case upon the terms of this Agreement, and CRT wishes to grant such rights to AchillesTx and does so with the consent and support of UCL, UCLB, CRICK, CS, KP and SQ.
Dated ___________________________ 2021 ACHILLES THERAPEUTICS PLC and IRAJ ALI SERVICE AGREEMENT GQ|Litter 21 Ironmonger Lane London EC2V 8EY Tel: 0203 375 0330 gqemploymentlaw.comService Agreement • March 1st, 2021 • Achilles Therapeutics PLC • Biological products, (no disgnostic substances) • England
ACHILLES TX LIMITED AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 1st, 2021 • Achilles Therapeutics PLC • Biological products, (no disgnostic substances) • New York
THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered on the ___ day of February 2021, by and among ACHILLES TX LIMITED (Company no. 13027460) (the “Company”), ACHILLES THERAPEUTICS UK LIMITED (Company no. 10167668) (“ATUK”), CANCER RESEARCH TECHNOLOGY LIMITED (“CRT”) (Company no. 01626049) and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor” (together, the “Parties”).
DATED 28th February 2020 - and - COLLABORATION AGREEMENTCollaboration Agreement • March 1st, 2021 • Achilles Therapeutics PLC • Biological products, (no disgnostic substances) • England and Wales
Eversheds Sutherland (International) LLP One Wood Street London EC2V 7WS United Kingdom T: +44 20 7497 9797 F: +44 20 7919 4919 DX 154280 Cheapside 8 eversheds-sutherland.com Dated: February 21, 2020Lease Agreement • March 1st, 2021 • Achilles Therapeutics PLC • Biological products, (no disgnostic substances) • England and Wales
This Amendment Two is effective from 22 February 2024 BETWEEN:Collaboration Agreement • April 4th, 2024 • Achilles Therapeutics PLC • Biological products, (no disgnostic substances)
